Induction of mucosal immunity by intranasal immunization with recombinant adenovirus expressing major epitopes of Porcine circovirus-2 capsid protein
Induction of mucosal immunity by intranasal immunization with recombinant adenovirus expressing major epitopes of Porcine circovirus-2 capsid protein
复制标题
表达猪圆环病毒-2衣壳蛋白主要表位的重组腺病毒鼻内免疫诱导粘膜免疫
DOI：
10.1016/j.vetimm.2013.03.015
复制
发表时间：
2013-07-15
影响因子：
1.8
通讯作者：
Wang, Chuan-qing
中科院分区：
文献类型：
--
作者：
Liu, Yu-feng;Guo, Quan-hai;Wang, Chuan-qing
猪圆环病毒2型（PCV-2）主要通过粘膜传播，因此粘膜免疫可能是PCV-2免疫策略的基本特征。表达PCV-2衣壳蛋白主要表位的重组复制缺陷型腺病毒（rAd/Cap/518）经鼻内（i.n.）诱导的粘液免疫，肌内（i.m.）或口服途径进行评价。通过i.n.用rAd/Cap/518免疫免疫组唾液、支气管肺泡和肠灌洗液中伊加滴度均高于免疫组。路线经腹腔注射rAd/Cap/518后，小鼠外周血中CD 3+、CD 3 + CD 4+和CD 3 + CD 8 + T细胞比例明显升高。与对照组比较。在经i.n.注射rAd/Cap/518免疫的小鼠的脾和肠系膜淋巴结中检测到较高水平的IFN-γ。与其他组相比，IL-4在任何组中均未检测到。实时PCR分析证实了i.m.或I.N.免疫组低于rAd免疫组。这些结果表明，i.n.施用rAd/Cap/518可以在小鼠的全身和粘膜免疫区室中引发体液和Th 1型细胞保护性免疫，代表了针对PCV-2的有希望的粘膜疫苗候选物。(c)2013爱思唯尔有限公司版权所有。
Porcine circovirus-2 (PCV-2) is primarily transmitted through mucosa, thus the mucosal immunity may constitute an essential feature of vaccination strategies against PCV-2 infection. Mucosal immunity elicited by recombinant replication-deficient adenovirus expressing the major epitopes of PCV-2 capsid protein (rAd/Cap/518) via intranasal (i.n.), intramuscular (i.m.) or oral routes in mice were evaluated. Immunization with rAd/Cap/518 via i.n. route induced higher titers of IgA in saliva, bronchoalveolar and intestinal lavage fluid compared with those immunized via i.m. route. The proportions of CD3+, CD3+CD4+ and CD3+CD8+ T cells were significantly increased in mice immunized with rAd/Cap/518 via i.n. route compared with the control group. Higher levels of IFN-gamma were detected in the spleen and mesenteric lymph nodes of mice immunized with rAd/Cap/518 via i.n. route compared with other groups, yet IL-4 was not detected in any group. Real-time PCR analysis confirmed viral DNA loads in the i.m. or i.n. immunization group was lower than that seen in the rAd immunization. These results indicate that i.n. administration of rAd/Cap/518 can elicit humoral and Th1-type cellular protective immunity in both systemic and mucosal immune compartments in mice, representing a promising mucosal vaccine candidate against PCV-2. (c) 2013 Elsevier B.V. All rights reserved.